- Connecticut AG William Tong announced a settlement with Triggered Brand following allegations that the company unlawfully advertised and sold counterfeit GLP-1 weight loss drugs in violation of state consumer protection laws.
- According to the AG’s press release, the settlement resolves a lawsuit that AG Tong filed in May 2025 alleging that Triggered sold the counterfeit GLP-1 drugs to consumers without proper medical oversight and safety controls. AG Tong warned consumers against purchasing GLP-1 medications without a prescription, citing significant health and safety concerns, and stated that his office will continue to investigate other bootleg sellers of the drugs. Under the settlement, the company must cease all sales of “bootleg” GLP-1 medications and pay a $300,000 judgment, which will be suspended after $18,500 unless Triggered violates the terms.
- We previously reported on AG Tong’s enforcement actions against companies that allegedly advertised, distributed, or sold so-called “research grade” versions of GLP-1s, as well as a letter sent by a bipartisan coalition of 38 AGs requesting that the FDA act to protect consumers from counterfeit GLP-1s.
- On Cozen O’Connor’s State AG Pulse podcast, State AG Group attorney Keturah Taylor spoke with Cozen O’Connor colleagues Danielle Sapega and Rick Van Buren about federal and state GLP-1 regulation and enforcement, as well as a roadmap to help legitimate market participants avoid pitfalls.